IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report

Journal of Clinical Oncology

Volumn 27, Issue 31, 2009, Pages 5202-5207

  Martinelli, Giovanni ^a   Iacobucci, Ilaria ^a   Storlazzi, Clelia Tiziana ^a   Vignetti, Marco ^a   Paoloni, Francesca ^a   Cilloni, Daniela ^a   Soverini, Simona ^a   Vitale, Antonella ^a   Chiaretti, Sabina ^a   Cimino, Giuseppe ^a   Papayannidis, Cristina ^a   Paolini, Stefania ^a   Elia, Loredana ^a   Fazi, Paola ^a   Meloni, Giovanna ^a   Amadori, Sergio ^a   Saglio, Giuseppe ^a   Pane, Fabrizio ^a   Baccarani, Michele ^a   Foà, Robin ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; IKAROS TRANSCRIPTION FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IKZF1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 7P; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EXON; FEMALE; GENE DELETION; GENE IDENTIFICATION; GENE SEQUENCE; GENOME; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; GENE DELETION; GENE EXPRESSION PROFILING; HUMANS; IKAROS TRANSCRIPTION FACTOR; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHILADELPHIA CHROMOSOME; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 70449719091     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.6408     Document Type: Article

References (27)

1. Nowell PC, Hungerford DA: Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 25:85-109, 1960
2. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999
3. Groffen J, Stephenson JR, Heisterkamp N, et al: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99, 1984
4. Chan LC, Karhi KK, Rayter SI, et al: A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 325: 635-637, 1987
5. Clark SS, McLaughlin J, Crist WM, et al: Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 235:85-88, 1987
6. Cortes M, Wong E, Koipally J, et al: Control of lymphocyte development by the Ikaros gene family. Curr Opin Immunol 11:167-171, 1999
7. Vignetti M, Fazi P, Cimino G, et al: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosomepositive patients with acute lymphoblastic leukemia without additional chemotherapy: Results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 109:3676-3678, 2007
8. le Coutre P, Ottmann OG, Giles F, et al: Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant acceleratedphase chronic myelogenous leukemia. Blood 111: 1834-1839, 2008
9. Piccaluga PP, Paolini S, Martinelli G: Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 110:1178-1186, 2007
10. Ottmann O, Dombret H, Martinelli G, et al: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood 110:2309-2315, 2007
11. Ottmann OG, Wassmann B: Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: Current status and evolving concepts. Best Pract Res Clin Haematol 15:757-769, 2002
12. Thomas X: Acute lymphoblastic leukemia with Philadelphia chromosome: Treatment with kinase inhibitors. Bull Cancer 94:871-880, 2007
13. Pane F, Cimino G, Izzo B, et al: Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 19:628-635, 2005
14. Mullighan CG, Miller CB, Radtke I, et al: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114, 2008
15. Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009
16. Georgopoulos K, Bigby M, Wang JH, et al: The Ikaros gene is required for the development of all lymphoid lineages. Cell 79:143-156, 1994
17. Molnár A, Wu P, Largespada DA, et al: The Ikaros gene encodes a family of lymphocyte-restricted zinc finger DNA binding proteins, highly conserved in human and mouse. J Immunol 156: 585-592, 1996
18. Westman BJ, Mackay JP, Gell D: Ikaros: A key regulator of haematopoiesis. Int J Biochem Cell Biol 34:1304-1307, 2002
19. Kaufmann C, Yoshida T, Perotti EA, et al: A complex network of regulatory elements in Ikaros and their activity during hemo-lymphopoiesis. Embo J 22:2211-2223, 2003
20. Iacobucci I, Lonetti A, Messa F, et al: Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: Implications for a new mechanism of resistance. Blood 112:3847-3855, 2008
21. Iacobucci I, Ottaviani E, Astolfi A, et al: Highresolution genomic profiling of Ph-positive acute lymphoblastic leukaemia (ALL) identified recurrent copy number anomalies in genes regulating the cell cycle and the B-cell differentiation. Haematologica 93:1084, 2008 (abstr)
22. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Iacobucci I, Storlazzi C, Cilloni D, et al: Identification and molecular characterisation of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukaemia patients: On behalf of GIMEMA ALL WP. Blood 10.1182/blood-2008-08-173963 [epub ahead of print on July 9, 2009]
24. Martinelli G, Soverini S, Rosti G, et al: Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 19:1872-1879, 2005
25. Faderl S, Jeha S, Kantarjian HM: The biology and therapy of adult acute lymphoblastic leukemia. Cancer 98:1337-1354, 2003
26. Smale ST, Dorshkind K: Hematopoiesis flies high with Ikaros. Nat Immunol 7:367-369, 2006
27. Gomez-del Arco P, Maki K, Georgopoulos K: Phosphorylation controls Ikaros's ability to negatively regulate the G(1)-S transition. Mol Cell Biol 24:2797-2807, 2004